RxDoctor Payments Data

Tamryn Anderson

Psychiatric/Mental Health · Breckenridge, TXNPI 1457981458

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,000 of the $13,042 with a category attached, or 76.7%. AbbVie accounts for 87.4% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $11,264, more than ten times the $297 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,042in general payments, 2019–2025

Across 120 payments — averaging $108.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Neurocrine Biosciences, Inc.$575
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$218
  • Otsuka America Pharmaceutical, Inc.$145
  • Alkermes, Inc.$142
  • Teva Pharmaceuticals USA, Inc.$98
  • plus $466 from 11 others

What the payments were for

  • Speaking & faculty fees$10,00077%
  • Travel & lodging$9687%
  • Food & beverage$2,07116%
  • Education$30%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,042 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole20$58,643
RexultiBrexpiprazole19$30,546
VraylarCariprazine Hcl20$24,764
TrintellixVortioxetine Hydrobromide13$7,285
Aripiprazole17$6,493
BelsomraSuvorexant12$5,493
Atomoxetine Hcl23$1,116
Duloxetine Hcl87$1,021
Lamotrigine127$914
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$501
Mirtazapine21$487
Trazodone Hcl62$400
Sertraline Hcl54$387
Olanzapine33$333
Gabapentin22$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$145$89,18939 claims
AbbVieVraylar$11,399$24,76420 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$59$7,28513 claims
MerckBelsomra$13$5,49312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Breckenridge

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →